TIBCS 2025

Program
Time (UTC+8) Topic Speaker Moderator Abstract Slides Video
08:00 - 08:30 Registration
08:30 - 08:40 Opening Ceremony
Fang-Ming Chen
08:40 - 09:00 [Keynote Speech] Right Choice Beyond Survival: How Taiwan is Pioneering Quality and Equity in Breast Cancer Care Through Value-Based Reform
Chung-Liang Shih
Ming-Feng Hou
09:00 - 09:30 Session(1) Early Onset Breast Cancer: Current Knowledge and Gaps
Kyong Hwa Park
King-Jen Chang
09:30 - 10:00 Session (1) Role of Platinum in Adjuvant/Neoadjuvant Treatment in TNBC
Joohyuk Sohn
Shyr-Ming Sheen-Chen
10:00 - 10:40 Session (1) Redefining the Role of TKIs in HER2-Positive mBC: From Systemic Control to CNS Penetration
Nancy Lin
Tsu-Yi Chao
10:40 - 11:00 Coffee Break
11:00 - 11:40 Session (2) Navigating the Complexities of Treatment in HR+ HER2- Metastatic Breast Cancer: Tailoring CDK4/6 Inhibitors to Meet Individual Patient Needs
Hope S. Rugo
Hsien-Tang Yeh
11:40 - 12:20 Session (2) The Practice of Treating HR+/HER2- Early Breast Cancer is Evolving: Boardening the Impact of CDK4/6 Inhibitors
Peter Fasching
Fang-Ming Chen
12:20 - 13:05 Luncheon Symposium (1) Maximizing Treatment Benefit and Overall Survival in HER2- Negative MBC
Hsu-Huan Chou
Dar-Ren Chen
13:05 - 13:20 Coffee Break
13:20 - 14:00 Session (2) The Sustainable Efficacy of CDK4/6 Inhibitor in HR+/Her2- Node+ High Risk Early Breast Cancer
Michael Gnant
Shin-Cheh Chen
14:00 - 14:30 Session (2) Personalized Neo-Adjuvant Strategies for Hormone Receptor-Positive Early Breast Cancer
Marc Thill
Shigehira Saji
14:30 - 15:10 Session (2) Choosing Wisely:TS-1 for HR+ EBC
Kun-Ming Rau
Hsien-Kun Chang
15:10 - 15:30 Coffee Break
15:30 - 16:10 Session (2) Transforming Treatment Landscape of HR+ mBC: Integrating Genomic Biomarkers to Drive Precision Medicine
Naoto T. Ueno
Chiun-Sheng Huang
16:10 - 16:50 Session (2) The Next Wave of Endocrine and Target Therapy for HR+/HER2- Metastatic Breast Cancer
Peter Schmid
Ling-Ming Tseng
16:50 - 17:30 Session (3) Unlocking the Potential of ADC: Transforming Breast Cancer Outcomes Across HER2 Expression Spectrum (MBC)
Naoto T. Ueno
Yen-Shen Lu
17:30 - 18:00 Session (3) Current Status and Emerging Approaches in HER2+ Metastatic Breast Cancer
Giampaolo Bianchini
Ta-Chung Chao
Time (UTC+8) Topic Speaker Moderator Abstract Slides Video
10:10 - 10:30 [TBCS-GBCC Joint Session] Axillary management following NAC: Surgical Oncologists’ point of views
Jai Min Ryu
Wonshik Han
Guo-Shiou Liao
10:30 - 10:50 [TBCS-GBCC Joint Session] Axillary management following NAC: Medical Oncologists’ point of views
Sung Hoon Sim
Wonshik Han
Guo-Shiou Liao
10:50 - 11:10 [TBCS-GBCC Joint Session] Axillary management following NAC: Radiation Oncologists’ point of views
Tzu-Yu Lai
Wonshik Han
Guo-Shiou Liao
11:10 - 11:30 [TBCS-GBCC Joint Session] Wrap up: Current guidelines of Axillary management following NAC
Judy C. Boughey
Wonshik Han
Guo-Shiou Liao
11:30 - 12:00 [TBCS-GBCC Joint Session] Panel Discussion
Wonshik Han
14:00 - 14:05 [Young Doctors Forum] Opening
Chi-Cheng Huang
Chi-Cheng Huang
14:05 - 14:30 [Young Doctors Forum] Beyond the White Coat: Challenges Facing Young Female Breast Oncologists and How to Address Them
Kelly Hunt
14:30 - 14:55 [Young Doctors Forum] Global Perspectives: Navigating Career Pathways in Breast Cancer Treatment for Young Doctors
Tristen Park
14:55 - 15:00 [Young Doctors Forum] Q&A
An-Chieh Feng
15:00 - 15:05 Coffee Break
15:05 - 16:30 [Young Doctors Debate] Should ALND Be Performed in ypN1micro Luminal Breast Cancer Patient with initial cN1 After Neoadjuvant Chemotherapy?
Han-Fang Cheng
Tuguldur Dashzeveg
Ruoh-Yun Gau
Jeffrey Hing Jun Xian
Chih-Hao Huang
Hsiang-Wei Huang
Chieh-Ni Kao
Mai Kitazawa
Young-Won Lee
Ting-Yi Liao
Yi Ping Lim
Zhu-Jun Loh
Hitomi Mori
Batsukh Pushkin
Hsueh-Han Tsai
Jennifer Tseng
Asdi Wihandono
Doyoun Woen
Wen-Pei Wu
Wen-Chi Yang
Chiao Lo
15:45 - 16:25 [Young Doctors Debate] Should adjuvant chemotherapy be avoided in this patient given her low recurrence score, despite the presence of nodal micrometastasis?
Dahn Byun
Adrianne Carmel Y. Cabrera
Fu-Ming Cheng
Saranzaya Damdin
Desak Gede Agung Pramesti Devi
Thu Hang Hoang
Chia-Yen Hung
Kibum Kim
Kyunghwan Kim
Yoshie Kobayashi
Seung Ah Lee
Chia-Chen Li
Su Min Lee
Wei-Nung Liu
Donghyeon Oh
Kaori Tane
I-Chen Tsai
Chan-Keng Yang
Ming-Han Yang
Shih-Yu Huang
Chun-Yu Liu
16:25 - 16:30 Closing
Jeong Eon Lee
16:30 - 17:00 Group Photo
Time (UTC+8) Topic Speaker Moderator Abstract Slides Video
10:30 - 10:40 Epigenetic inhibition of PLK1 by Luteolin-7-glucoside suppresses Estrogen receptor-positive breast cancer progression and proliferation.
Joseph Lin
10:40 - 10:50 Preliminary spatial transcriptomic analysis for invasive lobular carcinoma
Chi-Cheng Huang
10:50 - 11:00 The Role of miRNAs in breast cancer across distinct subtypes via microarray analysis
Chi-Cheng Huang
11:00 - 11:10 Discovery of BRCA Founder Variants in Taiwanese Cancer Patients: Clinical Actionability and Population Screening Implications from 84-Gene Panel Analysis
Peng-Yu Chen
11:10 - 11:20 Clinical Relevance of PIK3CA Mutations in Modulating CDK4/6 Inhibitor Efficacy in HR+/HER2− Advanced Breast Cancer
Sheng-Fan Wang
11:20 - 11:30 Toosendanin inhibits the metastatic progression of triple-negative breast cancer by abrogating ADORA2A-driven neurogenesis
Juan Zhang
11:30 - 11:40 The adoption rate and management of treatment-emergent adverse event during adjuvant abemaciclib treatment in Japanese women with high-risk HR+HER2- early breast cancer
Kaori Tane
11:40 - 11:50 Features of Breast Cancer Across Age Groups in a Japanese Hospital: Comparison with Global Trends
Hitomi Mori
11:50 - 12:00 Evaluation of a Novel Diagnostic Kit Using the Semi-Dry Dot-Blot Method with an Automated Reader for Detecting Breast Cancer Metastases in Sentinel Lymph Nodes: A Combined Analysis of Two Multicenter Prospective Studies in Japan
Ryota Otsubo
12:00 - 12:10 Real-World Effectiveness and Safety of Neoadjuvant Pembrolizumab plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: Updated Data from a Single-Center Taiwanese Cohort
Han-Fang Cheng
12:10 - 12:20 From AI to Single-Cell and Multi-Omics: RAC1 as a Prognostic and Therapeutic Target in Breast Cancer Oncometabolism and Immunomodulation
Hung-Yu Lin
12:20 - 12:30 Impact of psychiatric disorders on metastatic breast cancer survival: the critical role of supportive psychiatric management
Cho-Hao Lee
12:30 - 13:30 Lunch & Coffee Break
13:10 - 13:20 Adipocyte-Derived SERPINE1 Drives Obesity-Associated Breast Cancer Progression: Integrative Transcriptomic and Functional Analyses
Kian Hwee Chong
13:20 - 13:30 Immunogenic Effect of PIK3CA Mutations in Breast Cancer: Implications for Neoantigens, HLA Types, and Immune Microenvironment
Hsing-Wu Chen
13:30 - 13:40 Use of pre-treatment MRI-derived radiomics to predict the final treatment response to neoadjuvant chemotherapy in breast cancer patients: a preliminary study
Jane Wang
13:40 - 13:50 SHMT2 Promotes Breast Cancer Metastasis through Metabolic Reprogramming and EMT Activation
Yen-Dun Tzeng
13:50 - 14:00 Mature B cell with the antigen presenting signature predicts pathologic complete response and survival in early Her2-positive breast cancer treated with neoadjuvant therapy
Po-Han Lin
14:00 - 14:10 Novel HER2 activity linked to therapy resistance and brain metastasis
Huynh Kieu Thanh
14:10 - 14:20 Disrupting DDB2–DNA Interaction by Lapatinib Enhances Chemotherapy Sensitivity
Yu-Hao He
14:20 - 14:30 Age-informed real-world evidence reveals TP53 mutation confers resistance to CDK4/6 but not immune checkpoint inhibitors in ER-positive/HER2-negative breast cancer
Masanori Oshi
14:30 - 14:40 Dual Metabolic Reprogramming in Metastatic Breast Cancer: The Critical Role of ANT2 in Supporting Energy Homeostasis and Progression
Chia-Jung Li
14:40 - 15:00 Coffee Break
15:00 - 15:10 Spatial transcriptomics reveals clone-specific features of primary and metastatic tumors in triple-negative breast cancer
Yu-Wen Weng
15:10 - 15:20 SCD1-driven lipid metabolic reprogramming confers resistance to HER2-targeted therapies in breast cancer
Meng-Xia Su
15:20 - 15:30 Sacituzumab govitecan in HR-positive/HER2-negative breast cancer cells with resistance to PI3K or AKT inhibitors
Wei-Pang Chung
15:30 - 15:40 Tartrate-resistant acid phosphatase 5 regulates the metabolic flexibility of macrophages in the tumor microenvironment, thereby influencing their functional fate and modulating tumor growth.
Ming-Shen Dai
15:40 - 15:50 What We Learned from AJCC 8th Edition Cancer Staging System for Our Breast Cancer Patients (2005-2021)
Ben-Long Yu
15:50 - 16:00 Cohort Study on Adjuvant Treatment for Premenopausal HR positive/HER2 negative Breast Cancer Patients with 1-3 Positive Nodes
Ping-Fu Yang
Time (UTC+8) Topic Speaker Moderator Abstract Slides Video
11:10 - 11:50 Let’s Meet the Master (1) Marc Thill
13:30 - 14:10 Let’s Meet the Master (2) Judy C. Boughey
Wen-Ling Kuo
14:40 - 15:20 Let’s Meet the Master (3) Giampaolo Bianchini
Jiun-I Lai
16:10 - 16:50 Let’s Meet the Master (4) Peter Fasching
Time (UTC+8) Topic Speaker Moderator Abstract Slides Video
08:10 - 08:50 Breakfast Symposium: Beyond Cancer-Related Fatigue: Exploring Immunomodulatory Strategies to Reshape Breast Cancer Care
Ming-Shen Dai
Kun-Ming Rau
08:50 - 09:20 Session (4) The Surgeon's Role in Locoregional Management of Stage IV Breast Cancer
Mehra Golshan
Takashi Ishikawa
09:20 - 09:50 Session (4) Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant Chemotherapy
Judy C. Boughey
Jyh-Cherng Yu
09:50 - 10:05 Coffee Break
10:05 - 10:35 Session (4) Omission of Radiation Therapy Post Breast Conserving Surgery
Boon Chua
Shou-Tung Chen
10:35 - 11:05 Session (4) Setting the Standard for the Future of Cancer Surgery
Kelly Hunt
Fiona Tsui-Fen Cheng
11:05 - 11:45 Session (5) Shifting Paradigms in mTNBC - Advancing Sacituzumab Towards the Frontline
Sherene Loi
Chin-Yao Lin
11:45 - 12:25 Session (5) A New Era in the Treatment of Metastatic Triple-Negative Breast Cancer: Who, When, and Why to Use Immunotherapy and Antibody-Drug Conjugates
Sung Bae Kim
Chun-Yu Liu
12:25 - 13:10 Luncheon Symposium (2) Advances in Dual HER2 Inhibition: Shaping the Future of HER2-Positive Breast Cancer Care
Chih-Chiang Hung
Ming-Yang Wang
13:10 - 13:30 Coffee Break
13:30 - 14:10 Session (6) Breaking the Ceiling: Strategies to Reduce Recurrence in HER2+ Early Breast Cancer
Chi-Cheng Huang
Yuan-Ching Chang
14:10 - 14:50 Session (6) HER2+ Breast Cancer in the Era of Biosimilars: Optimizing Access with Herzuma
Ching-Ting Wei
Chao-Ming Hung
14:50 - 15:05 Coffee Break
15:05 - 15:45 Session (6) Optimizing HER2 Management Among Breast Cancer Patients: Role of Trastuzumab in Evolving Therapeutic Paradigms
Paul Cornes
Wen-Hung Kuo
15:45 - 16:25 Session (6) From Evidence to Action: Impact of Xgeva in Breast Cancer Bone Metastasis
I-Chen Tsai
Kuo-Ting Lee
16:25 - 16:45 Award Ceremony
16:45 - 17:00 Closing
Time (UTC+8) Topic Speaker Moderator Abstract Slides Video
09:35 - 10:15 Reimbursement Expansion of Pegfilgrastim for FN Prevention in Non–Myeloid Malignancies: Broader Access, Better Outcomes
Chih-Hao Huang
Chih-Chiang Hung
10:15 - 10:55 New Horizons in First-Line Management of HR+ mBC with PIK3CA Mutation
Shih-Che Shen
Yan-Ang Chen
10:55 - 11:35 Immunotherapy in Early TNBC: Evolving Evidence, Maximizing Benefit Through Thoughtful Patient Selection
Han-Fang Cheng
Ling-Ming Tseng
11:35 - 12:15 Suture Scaffold Technique in Breast-Conserving Surgery: Safety, Cosmetic Outcomes, and Lessons from Over 2,000 Cases
Reiko Mitsueda
Chen-Hsiang Chang
12:15 - 13:10 Emerging Approaches in ER+/HER2- Metastatic Breast Cancer Management
Soo Chin Lee
Wei-Pang Chung
13:10 - 13:50 Not all CDK4/6i are created equal: Optimizing HR+ HER2- Metastatic Breast Cancer Treatment Outcomes
Michael Gnant
Ching-Hung Lin
13:50 - 14:30 Oncofertility Needs and Supportive Care for Breast Cancer Women in Reproductive Age: The Experience from Hope Foundation for Cancer Care in Taiwan
Shiuyu C. Katie Lee
Yao-Jen Chang
14:30 - 15:10 Survivorship in Breast Cancer: Physical Activity and Alcohol Consumption and Breast Cancer
Tristen Park
Liang-Chih Liu
15:10 - 15:50 Cardio-Oncology at NCKUH: Breast Cancer and Cardiotoxicity - Progress and Future Directions
Yu-Ling Hsu
Chin-Sheng Hung